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ABSTRACT 
Persistent pain remains a major health issue: the common treatments relying on either 
repeated local injections or systemic drug administration are prone to concomitant side-
effects. It is thought that an alternative could be a multifunctional cargo system to 
deliver medicine to a target site and release it over a prolonged time window. We nano-
engineered microcapsules equipped with adjustable cargo release properties and 
encapsulated the sodium channel blocker QX-314 using the layer-by-layer (LbL) 
technology. First, we employed single-cell electrophysiology to establish in vitro that 
microcapsule application can dampen neuronal excitability in a controlled fashion. 
Secondly, we used two-photon excitation imaging to monitor and adjust long-lasting 
release of encapsulated cargo in target tissue in situ. Finally, we explored an 
established peripheral inflammation model in rodents to find that a single local injection 
of QX-314-containing microcapsules could provide a robust pain relief lasting for over a 
week. This was accompanied by a recovery of the locomotive deficit and the 
amelioration of anxiety in animals with persistent inflammation. Post-hoc 
immunohistology confirmed biodegradation of microcapsules over a period of several 
weeks. The overall remedial effect lasted 10-20 times longer than that of a single focal 
drug injection. It depended on the QX-314 encapsulation levels, involved TRPV1-
channel-dependent cell permeability of QX-314, and showed no detectable side-effects. 
Our data suggest that nano-engineered encapsulation provides local drug delivery 
suitable for prolonged pain relief, which could be highly advantageous compared to 
existing treatments. 
 
Keywords: biodegradable microcapsules, persistent pain, Na+ channels, drug diffusion, 
neuronal excitability, pain relief, locomotive deficit and anxiety. 
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INTRODUCTION 
Persistent or chronic pain remains largely resistant to treatment. In practice, the 
analgesics of choice have been opiates and Na+ channel blockers, such as lidocaine. 
However, their use has been restricted by side-effects, such as sedation for opiates and 
cardiotoxicity for lidocaine and its derivatives. These factors curtail the amount 
administered, mainly due to the risk of a rapid systemic escape from the target site or 
from a drug depot. Furthermore, existing methods of focal drug application have 
principal limitations: singular injections provide poor control over the application kinetics 
whereas chronic injecting devices are invasive, costly, and are prone to the infection 
risk.  
Over the years, various medicine cargo systems have been explored and tested for 
their capability of targeted drug delivery (Sukhorukov et al., 2005, Tanbour et al., 2016), 
including pain treatment. Some notable attempts utilized hydrogels involving steroid 
treatment (Liu et al., 2016), photo-triggered liposomes carrying Na+ channel blocker 
tetrodotoxin (Rwei et al., 2015, Zhan et al., 2016), or immunoliposomes for opioid 
delivery (Hua and Cabot, 2013). A major challenge has been, however, to incorporate 
multiple functionalities into a single entity, which would deliver medicine to the target 
site and release it over a relatively long period, in a controllable fashion (Sukhorukov et 
al., 2005, Sukhorukov and Mohwald, 2007, Stuart et al., 2010). One promising direction 
has been biodegradable polyelectrolyte-based microcapsule systems constructed with 
the layer-by-layer (LbL) method (Decher, 1997, Stuart et al., 2010). Such systems could 
incorporate different polyelectrolytes and charged nanoparticles in a single LbL capsule 
combining several functionalities. A wide variety of substances have successfully been 
tried as cargo for encapsulation (De Cock et al., 2010).  
In brief, the LbL microcapsules could be made controllably to a size of 0.3 µm or larger, 
with the outer layers providing their functional features, such as varied permeability 
(cargo release rate) or sensitivity to the external stimuli (pH, temperature, osmolarity, 
light, etc.) (Munoz Javier et al., 2008; Antipina and Sukhorukov, 2011a; Delcea et al., 
2011a; Pavlov et al., 2011; Pavlov et al., 2013; Gao et al., 2016b). The microcapsules 
are routinely made of biodegradable components and show no toxicity or appreciable 
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inflammation or apoptotic effects when injected in tissue or internalized by cultured cells 
(Pavlov et al., 2011). 
Among the analgesics used for local pain treatment there has been a growing interest in 
the Na+ channel blocker QX-314, which appears to produce relatively long-lasting 
analgesic effects, at relatively higher potency, in animal models (Lim et al., 2007b; 
Roberson et al., 2011b; Zhao et al., 2014a). Whilst QX-314 is membrane-impermeable 
and blocks Na+ channels from the cytoplasm side, studies in situ have established that it 
enters nerve cells through the transient receptor potential (TRP) receptors TRPV1 and 
TRPA1 (Binshtok et al., 2007a; Leffler et al., 2011a; Puopolo et al., 2013; Stueber et al., 
2016), which are strongly expressed in peripheral nociceptors (pain-signaling neurons), 
but also through a TRP-independent mechanism (Brenneis et al., 2014b; Hofmann et 
al., 2014a). These findings have prompted calls for further validation of this potentially 
efficient analgesic (Roberson et al., 2011b; Stueber et al., 2016). 
Notwithstanding the promise of LbL encapsulation technology, there have been no 
systematic attempts to adapt it to the explorative studies of therapeutic intervention. We 
therefore set out to test whether drug delivery via nano-engineered LbL microcapsules 
has a therapeutic potential in the context of pain treatment. Here we encapsulate QX-
314 in biodegradable microcapsules made of poly-l-arginine and dextran sulphate, 
adjust and test its release action in vitro and in situ, and document the effects of 
encapsulated QX-314 (injected subcutaneously) in a persistent inflammatory pain model 
in rodents in vivo.
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MATERIALS AND METHODS 
Design and fabrication of microcapsules 
Polymer-based multilayer microcapsules were fabricated in accord with the previously 
established LbL assembly technique (Sukhorukov and Mohwald, 2007, Stuart et al., 
2010). Quaternary lidocaine derivative QX-314 chloride, the membrane-impermeable 
blocker of voltage-gated Na+ channels, was encapsulated at variable amounts (4 to 10 
pg per capsule). Briefly, CaCO3 was used as sacrificial templates, and poly-L-arginine 
(PArg) was deposited as the first layer and incubated for 15 min, then washed three 
times; the oppositely charged dextran sulphate sodium salt (DXS) was assembled as 
the second layer with the same procedure. In order to encapsulate QX-314 into the 
capsule shells, two of the DXS layers were substituted by QX-314 during the assembly 
process. Polymer solutions and QX-314 solutions were prepared at 2 mg/ml. For 
fluorescent visualization one of the PArg layers was labelled with TRITC. After the 
assembly of eight layers, the CaCO3 cores were removed with 0.2 M EDTA. The 
resulting microcapsule architecture was PArg/DXS/QX-314/DXS/QX-314/DS/PArg-
TRITC/DXS. Empty microcapsules (no payload) were used as control. The 
concentration of capsules in suspension was determined by a hemocytometer (density 
range 1.1-2.2×108 1/ml). The QX-314 encapsulation rate was calculated by measuring 
the remaining QX-314 in supernatants. The suspension of microcapsules was stored at 
4 °C. To assess the encapsulated cargo release rate, the microcapsules of a similar 
configuration were made, with one of the DXS layer substituted by Alexa Fluor 488 
hydrazide (ThermoFisher Scientific).  
 
Primary neuron cultures 
Hippocampal neurons were isolated from the Sprague-Dawley rat pups (P0 to P2 day-
old), in accordance with the European Commission Directive (86/609/EEC) and the 
United Kingdom Home Office (Scientific Procedures) Act (1986). Neurons were cultured 
in NeuroBasal A/B27-based medium on a rat astrocyte feeder layer at 37°C as 
described (Ermolyuk et al., 2013). Cultured neurons were placed in a recording 
chamber mounted on the stage of an Olympus BX51WI upright microscope (Olympus, 
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Japan) equipped with a LUMPlanFI/IR 40×0.8 objective coupled to an infrared DIC 
imaging system.  
 
Electrophysiology 
Electrophysiological recordings were carried out using a Multipatch 700B amplifier 
controlled by the pClamp 10.2 software package (Molecular Devices, USA). Recordings 
were made in a bicarbonate-buffered solution (aCSF) containing (in mM) 126 NaCl, 3 
KCl, 2 MgSO4, 2 CaCl2, 26 NaHCO3, 1.25 NaH2PO4, 10 D-glucose saturated with 95% 
O2 and 5% CO2 (pH 7.4; 300–310 mOsmol) at 31–33°C. The recording electrode 
resistance was 2.5-5 MΩ when filled with the intracellular solution containing (in mM) 
126 K-gluconate, 10 HEPES, 4 KCl, 4 MgCl2, 2 BAPTA, 4 Mg-ATP, 0.4 GTP-Na (pH 7.2 
with KOH, osmolarity ~290 mOsmol). For the intracellular delivery of microcapsules, the 
glass electrode tip was back-filled with a suspension of microcapsules supplemented to 
the intracellular solution. The presence of microcapsules at the pipette tip was 
confirmed by visualizing their TRITC (FITC) fluorescence (conjugated to the capsule 
shell) prior to the breaking into whole-cell mode. Once in whole-cell, neurons were 
monitored for changes in their intrinsic active and passive membrane properties using 
fast sampling (20 kHz) every 1–3 min, until the baseline had stabilized (40-50 minutes). 
The series of sub- and supra-threshold rectangular current pulses (500- to 1000-ms-
duration) of the gradually (stepwise) increased stimulus intensity were applied. The 
steady-state input resistance (Rinput) was estimated from the measured current-voltage 
relationship at various time points during the experiment. The maximal firing frequency 
and the corresponding (minimal) membrane voltage were monitored throughout. 
Changes in the action potentials (AP) shape were analyzed using the first AP spike 
responding to a slow-ramp input current (ramp slope 480 pA/s). 
 
Acute skin tissue preparation 
Peripheral tissue was taken from the plantar surface of the hind paw of Sprague-Dawley 
rats (21 to 25-day-old) following animal sacrifice. Tissue sections (300–350 µm 
Page 6 of 41






























































For Peer Review Only
 7
thickness) consisting of skin layers and the tissue beneath were cut using a tissue 
chopper (McIlwain Model TC752, Mickle Laboratory Engineering Co.). Acute slices were 
placed in the recording chamber mounted on the stage of an Olympus upright 
microscope (Olympus, Japan) and maintained in HEPES-based physiological buffer. 
 
Imaging of encapsulated drug release 
Microcapsules containing Alexa Fluor-488 (similar molecular weight to QX-314) were 
delivered into acute skin tissue in situ with a glass pipette positioned between epidermal 
and dermal layers. One-photon (confocal) or two-photon (2P) excitation fluorescent 
imaging was carried out with either a Radiance 2000 (Zeiss-Bio-Rad) or a Femto2D 
(Femtonics, Budapest) system optically linked to a Ti:Sapphire Mai-Tai femtosecond 
pulse laser (SpectraPhysics-Newport), with various digital zooms, appropriate emission 
filters, and excitation at λx
2P = 800 nm, as detailed earlier  (Zheng et al., 2015, Mishra et 
al., 2016). The z-stacks of fluorescent images were collected every 5-10 min using 
512×512 pixel frames (typically 30–50 optical sections in 1-µm z-steps) for time-lapse 
monitoring of Alexa Fluor 488 fluorescence upon microcapsule injection (overall, 5 to 8 
hours in situ). To provide a direct in situ comparison of the diffusion escape rates 
between non-capsulated and encapsulated Alexa Fluor 488, the former was injected 
between epidermal and dermal layers with another glass pipette near the 
microcapsules. In a separate set of experiments, microcapsules carrying Alexa Fluor 
488 were placed in glycerol (99%) and monitored using a fast-scanning confocal 
fluorescence microscope (750 to 1000 lines/sec) in a photon-count mode, as described.  
 
Animals in behavioral studies  
The animals used for behavioral studies were 2.5- to 3-month-old male Wistar rats. All 
animal procedures were approved by the local Animal Ethics Committee (Bogomoletz 
Institute of Physiology, Kyiv, Ukraine): there were performed in full compliance with the 
ethical guidelines of the International Association for the Study of Pain and the United 
States Public Health Service's Policy on Humane Care and Use of Laboratory Animals, 
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as detailed in our previous works (Park et al., 2009b, Kopach et al., 2012, Kopach et al., 
2016). Animal procedures were fully compliant with the European Commission Directive 
(86/609/ EEC) and the United Kingdom Home Office (Scientific Procedures) Act (1986).  
 
Experimental design of pain models in vivo 
To produce unilateral peripheral inflammation and persistent nociceptive 
hypersensitivity, 50–100 µl of complete Freund's adjuvant (CFA, Sigma Chemicals, St. 
Louis, USA) suspended in an oil-saline (1:1) emulsion was injected subcutaneously into 
the plantar side of one hind paw of rats (Kopach et al., 2013, Kopach et al., 2015, 
Kopach et al., 2016). Encapsulated QX-314 was injected as a post-treatment of 
nociceptive hypersensitivity (after induction of the CFA-induced peripheral 
inflammation). Different groups of animals received a single intraplantar injection of 
microcapsules (carrying QX-314 at various concentrations, or empty capsules) into the 
inflamed tissue of the hind paw, in a total volume of 50 µl (diluted in saline) at 1 d post-
CFA, the time point indicating inflammatory pain maintenance (Kopach et al., 2013, 
Kopach et al., 2016). A control group of the CFA-inflamed animals received a similar 
injection of non-capsulated QX-314 or 2% lidocaine. In a separate set of experiments, 
groups of non-inflamed animals (no CFA) received encapsulated QX-314 or empty 
microcapsules. To produce unilateral acute peripheral hypersensitivity of neurogenic 
origin, 50 µl of capsaicin (1.5 µg/µl, Sigma Chemicals) was injected intradermally into 
the plantar side of one hind paw. 
 
Pain assessment 
The peripheral thermal pain threshold was measured using the Hargreaves technique, 
as we described previously (Kopach et al., 2012, Kopach et al., 2016). Briefly, after an 
animal was habituated to a Plexiglas chamber (Biological Research Apparatus, Ugo 
Basile, Italy), an infrared heat stimulus was applied to the middle of the plantar surface 
of hind paw. The heat beam was automatically turned off when the animal lifted its paw. 
The time between the stimulus onset and the paw withdrawal was automatically 
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recorded: it represented the latency of nociceptive response (thermal pain threshold). 
Measurements were repeated 3-5 times for each hind paw, the values were averaged. 
 
Open-field test for animal’ explorative behavior and anxiety 
To assess the sensorimotor function and animal locomotive behavior, an open-field test 
(open-field arena) was used as detailed previously (Kopach et al., 2016). In brief, 
animals were placed in an open-field arena (a 75×75×40 cm wooden box with a digital 
camera attached above) and allowed to move freely over a predefined time period (10 
min). Recordings were analyzed with MATLAB software using in-house scripts. The 
following parameters were monitored and recorded to assess locomotion: the total 
distance travelled by an animal, the maximal speed, and the acceleration. The anxiety 
level was assessed by computing the ratio between the fractions of time spent in the 
arena center versus corners. 
 
Immunohistology 
The localization of microcapsules injected in vivo was examined with post-hoc 
immunohistology of the glabrous skin samples collected from the hind paw at different 
time points post-injection. The dissected glabrous skin tissue (~1 cm) was fixed in 3% 
PFA (1-2 days at 4°C). After fixation, samples were replaced into PBS containing 0.02% 
sodium azide and underwent a cryo-protection treatment (10% sucrose for 2 h, then 
20% - for 2 h, followed by 30% for overnight). Tissue was mounted in OCT and stored 
at –80°C until processed for cryo-sectioning. The transverse tissue sections (30-60 µm 
thick) were cut and collected as an ordered series. Floating tissue sections were rinsed 
with PBS at least 3 times/5’ each section and blocked with 1% BSA, 5% Donkey serum 
in 0.2% Triton X-100 PBS for 4 hours. The primary antibodies were mouse anti-PGP9.5, 
neuron cytoplasmic protein 9.5 (1:500; Merck Millipore U.K.). After incubation with 
primary antibodies (2 days at 4°C), tissue sections were incubated with the secondary 
antibodies (overnight at 4°C). Secondary antibodies were Alexa Fluor 488 from the 
same host (1:200 or 1:400; Invitrogen). The following day sections were washed, 
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unrolled and mounted on glass slides using Vectashield H-1400 (Vector). Tissue 
sections were scanned for both PGP9.5-positive structures and microcapsules using a 
Radiance 2000 imaging system (Zeiss-Bio-Rad) or Femto2D (Femtonics) imaging 
system using various digital zooms.  
 
Microcapsule biodegradability assay 
Tissue samples were collected at various time points post-injection (at 1, 5, and 10 
weeks), fixed and processed for immunohistology (see above). Special care was taken 
to make sure that the microcapsule injection parameters (microcapsule concentration in 
suspension, pressure pulse, etc.) were uniform across the tested samples. To gauge the 
spatial distribution of microcapsules across the peripheral tissue, we scanned the entire 
tissue volume (transverse tissue sections cut and collected in a serial order) containing 
all detectable capsules in a z-stack of individual focal x-y planes (3-µm z-step, total 
scanned volume of ~370 µm3) using a Femto2D (Femtonics) imaging system. The 
fluorescence distributed in the z direction thus reported the amount of fluorescently 
labelled capsules in the tissue volume.  
 
Statistics 
Unless indicated otherwise, summary data are presented as mean ± SEM (standard 
error of the mean) with n referring to the number of cells (in vitro experiments) or 
animals (in vivo experiments) in the group. Student’s t-test (two-tailed unpaired) was 
used to determine statistical difference between experimental groups.  The statistical 
difference between groups of experimental animals was analyzed by one-way or two-
way analysis of variance (ANOVA) followed by Bonferroni post hoc test or Fisher test 
where appropriate. A p value of less than 0.05 was considered as statistically significant 
for either test. 
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RESULTS 
Encapsulated QX-314 can gradually suppress neuronal excitability in vitro 
We fabricated polymeric LbL microcapsules and encapsulated the membrane-
impermeable Na+ channels blocker QX-314 within the penultimate shell layer (4-10 pg 
per capsule; Figure 1A). The latter was to enable controllable shell permeability for the 
encapsulated compound. After initial trials, the capsule shell composition was adjusted 
to provide a cargo release rate of 4-5% per hour (decay constant ~20 h), which was 
gauged by monitoring the escape of encapsulated fluorescent dye (Alexa Fluor 488, a 
similar molecular weight to QX-314, Figure 1B). 
To examine how the encapsulated QX-314 suppresses neuronal excitability, we 
delivered the microcapsules inside individual hippocampal neurons (primary culture) 
using a patch pipette in whole-c ll configuration (Figure 1C). Thus, we monitored cell 
excitability in real time starting shortly upon microcapsule injection, and compared test 
groups with control (i.e., cells injected with empty microcapsules, or no capsules, Figure 
1D-F). We found a gradual suppression of neuronal excitability, which progressed within 
15–20 min after injecting encapsulated QX-314, leading to a sharp drop in the maximum 
firing rate (n = 18 cells, p < 0.01 compared with either empty microcapsules, n = 12, or 
no capsules, n = 17; Figure 1D). In parallel, encapsulated QX reduced the spike 
amplitude and the spike overshoot (amplitude above 0 mV; n = 9, p < 0.001 compared 
to that with no capsules, n = 9; Figure 1E-F).  
We also confirmed that the cell input resistance remained stable over time and was not 
affected by the injection of empty capsules (Figure 2A-B). However, it gradually 
increased following injection of encapsulated QX-314, reflecting major ion channel 
blockade (n = 14, difference at p < 0.05 with the empty-microcapsule group, n = 15, or 
no-capsules group, n = 14; Figure 2C-D). In contrast, adding QX-314 directly to the 
intracellular solution (0.5 mM, and especially 5 mM, a commonly used concentration in 
whole-cell) suppressed spike generation almost immediately (Figure 2E-F). To replicate 
the slow progression of excitability blockade under encapsulated QX-314, intracellular 
concentration of non-encapsulated QX-314 had to be reduced at least 103-104-fold (to 
~500 nM; Figure 2F).  
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Microcapsule cargo release rate in skin tissue in situ 
Because our ultimate goal was to test the pain-relieving effects of encapsulated QX-
314, we first sought to establish the microcapsule cargo release properties in peripheral 
skin tissue in situ. To achieve this, we employed an acute skin tissue preparation from 
glabrous skin of the rat hind paw. Microcapsules with encapsulated Alexa Fluor 488 
were delivered through a micropipette between epidermal and dermal layers and 
monitored using two-photon excitation (2PE) fluorescence microscopy (Figure 3A). 
Microcapsules showed a release rate constant of ~14 h (slow component), as evaluated 
by the time-lapse fluorescence emission monitoring of the encapsulated Alexa Fluor 
488 in situ (Figure 3B). In contrast, Alexa Fluor 488 in a free solution injected nearby, 
directly into the tissue via a micropipette, was escaping at a rate of ~4.12 s (slow 
component; Figure 3C), i.e., ~104 times faster. In addition, we used photon counting 
(within ~1 µm focal plane), in line with procedures detailed earlier (Zheng et al., 2015), 
to document a build-up of the diffuse fluorescence profile in the vicinity of individual 
microcapsules (Figure 3D). Within ~7 h post-injection in situ, this profile was consistent 
with the slow cargo diffusion escape from the microcapsules reported above (Figure 
3E).  
 
Encapsulated QX-314 provides long-lasting pain relief in vivo  
To explore therapeutic potential of encapsulated QX-314, we turned to a well-
established experimental paradigm of the CFA-induced unilateral persistent peripheral 
inflammation (Park et al., 2009b, Kopach et al., 2012, Kopach et al., 2016). Following 
the intraplantar injection of CFA, animals displayed robust thermal hypersensitivity on 
the ipsilateral (but not contralateral) side, as evaluated by measuring the thermal pain 
threshold (see Methods). If left untreated, the hypersensitivity persisted at least over 11 
days (Figure 4A), and a single focal subcutaneous injection of the common analgesic 
lidocaine had no long-lasting effect (Additional Figure 1).   
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The CFA-inflamed animals were quasi-randomly sampled to receive a single injection of 
either encapsulated QX-314 or empty microcapsules into the sites of inflammation at 
one day (1 d) post-CFA. Animals that received encapsulated QX-314 showed 
substantially alleviated hypersensitivity, with a progressive recovery of the thermal pain 
threshold back to the pre-inflammatory level by the next day (n = 6 rats,  p < 0.01 
compared with the CFA-inflamed group injected either empty microcapsules, n = 5, or 
no capsules, n = 27; Figure 4A-B). Injecting empty capsules had no detectable effect (n 
= 6 rats, Figure 4A and Additional Figure 1A) whereas a single focal injection of 100 mM 
non-encapsulated QX-314 had only a brief and marginal relief of the thermal nociceptive 
hypersensitivity (n = 5 ats, p < 0.05 compared with no treatment at 2 d post-CFA; 
Figure 4A). We could routinely confirm with post-hoc immunohistology that 
microcapsules were scattered within the epidermal-dermal area as targeted (Figure 4C). 
Importantly, the therapeutic effect of encapsulated QX-314 remained significant for at 
least 12 days (p < 0.01 between the CFA-inflamed group injected with 3 mM 
encapsulated QX and that with empty microcapsules, over the experiment duration; 
Figure 4A) and its time course depended on the concentration of encapsulated QX-314 
(Figure 4B; p < 0.001 between the effects of 7.5 mM encapsulated QX-314, n = 7 rats, 
and empty microcapsules, over 11 days post-CFA; but no difference between 0.01 mM 
encapsulated QX-314, n = 5 and empty microcapsules over the 7-11 day period). 
Separate experiments showed how the effect depended on the amount of QX-314 
encapsulated per capsule (lasting over 12 days post-CFA for microcapsules containing 
10 pg of encapsulated QX-314: n = 8 rats, p < 0.01 compared with empty 
microcapsules, but up to 7 days  for 4.5 pg of encapsulated QX-314, n = 5 rats; Figure 
4D) and on the capsule size (Figure 4E; n = 6 rats, p < 0.01 for 2 µm microcapsules 
containing 3 mM of encapsulated QX-314 and n = 5 rats, p < 0.05 for 1 µm 
microcapsules compared with empty ones over the time of experiment).  
Control experiments confirmed that in healthy animals (no induced inflammation or 
pain), neither empty microcapsules (Additional Figure 2A) nor encapsulated QX-314 
(Additional Figure 2B) affected the peripheral thermal sensitivity, thus ruling out the 
concomitant effects of microcapsules per se. There were no acute (within hours) or 
delayed (days) effects on thermal sensitivity of the ipsilateral hind paw following 
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intraplantar injection of microcapsules as compared with the contralateral hind paw (no 
capsules) or with the zero time-point (before injection; Additional Figure 2).  
 
Encapsulated QX-314 rescues locomotive deficit and animal anxiety produced by 
peripheral inflammation 
We next examined whether the anti-nociceptive effect of encapsulated QX-314 
influences the locomotor deficit and the heightened anxiety, which is often associated 
with painful states (Kopach et al., 2016). We thus implemented an open-field test, a 
well-established assay for an integrative analysis of animal behavior, including anxiety 
(Figure 5A). The group of animals with the CFA-induced inflammatory pain showed a 
dramatic reduction in the trav lled distance (n = 5 rats, p < 0.01 for each recorded post-
CFA time point compared with zero time-point; Figure 5B) that persisted for at least 10 
days after CFA injection. An integrative analysis of animal behavior demonstrated that 
encapsulated QX-314 progressively rescued the impaired locomotion in inflamed 
animals within 2-4 days post-treatment (n = 5 rats, p < 0.05 compared with empty 
microcapsules; Figure 5B), in a dose-dependent manner (Figure 5C). This was 
consistent with the improved speed (Figure 5D) and acceleration (Additional Figure 3A). 
The effect was paralleled by a decline in the anxiety-like behavior, which was monitored 
as the proportion of time spent near the arena center, as opposed to corners (Figure 
5E). 
 
Anti-nociceptive effect of encapsulated QX-314 involves TRPV1 receptors  
Because QX-314 acts on Na+ channels from the intracellular side, it has to be 
transported into nerve fibers once released inside the tissue. The key established 
mechanism of this permeation involves transient receptor potential (TRP)-dependent 
receptors TRPV1 (Binshtok et al., 2007, Peters et al., 2014) and TRPA1 (Roberson et 
al., 2011, Brenneis et al., 2014), although the Toll-like receptor 5 could also contribute 
(Xu et al., 2015). First, we confirmed that the injected microcapsules rest near the 
peripheral nerve fibers (identified with neuron-specific PGP9.5 staining) innervating skin 
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tissue layers (Figure 6A). To determine whether the QX-314 action involves the TRP-
mediated pathway, we next used a model of neurogenic pain induced by capsaicin, a 
prototypic TRPV1 agonist (Frias and Merighi, 2016). 
Capsaicin (1.5 µg/µl) produced thermal hyperalgesia within a minute (n = 6 rats, p < 
0.01), with an immediate adverse reaction of the animal (licking, shaking the injected 
hind paw); the thermal hypersensitivity lasted up to 2–3 h, reversing back to control 
values (Figure 6B). QX-314 (7.4 mM, non-capsulated) co-injected with capsaicin rapidly 
produced anesthesia, which gradually developed into analgesia to a heat stimulus 
within 3-5 h post-injection (n = 6 rats, p < 0.05 compared with capsaicin at the 
corresponding time-points), fully consistent with previous observations (Binshtok et al., 
2007). The anti-nociceptive effect of QX-314 remained for several days (n = 6 rats, p < 
0.05 compared with capsaicin at 1 to 5 days post-injection; Figure 6B). In contrast to the 
complex cellular signaling mechanisms mediating the CFA-induced persistent 
inflammatory pain, the capsaicin-induced neurogenic pain should specifically involve 
TRPV1 activation at primary nociceptor afferents. Therefore, the most parsimonious 
explanation of the prolonged analgesic effect observed in this study is that QX-314, 
once injected subcutaneously, gets into the primary nociceptors through the activated 
TRPV1 receptors and retained inside nerve fibers.  
 
Microcapsules undergo progressive biodegradation post-injection in vivo 
The progressive and non-toxic biodegradation of the fabricated microcapsules is 
important for their safe biomedical use. The capsules of a similar design and polymer 
composition have already been validated for biodegradability and decomposition in 
human cell lines (De Cock et al., 2010, Pavlov et al., 2011, Gao et al., 2016). The 
constituent nanomaterials have also been tested for their low-toxicity biodegradation in 
vivo (Park et al., 2009a, Chiappini et al., 2015). To confirm the satisfactory 
biodegradation of microcapsules used here, a post-hoc immunohistology was carried 
out in tissue samples collected at different time-points after injecting microcapsules in 
vivo.  
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We assembled the integrated microcapsule fluorescence distributed in the z direction to 
gauge the amount of fluorescently labelled capsules in the tissue volume (total scanned 
volume of ~370 µm3). Five weeks or later post-injection, this distribution was reduced 
dramatically (Figure 6C; there was no detectable photo-bleaching of TRITC in individual 
remaining capsules at these time-points). In parallel, we monitored the average 
diameter of the remaining microcapsules (those with a distinguishable shape). As 
biodegradation of the multiple layers comprising the capsule shell is expected to start 
from the outer layer, it should gradually reduce the visible capsule size – this we 
precisely observed (p < 0.01 or p < 0.001 compared with the initial time-point, 3 h post-
injection; Figure 6D) as a confirmation of robust enzymatic decomposition of the 
microcapsule shell material within live tissue over a time post-injection. 
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DISCUSSION 
Improving the treatment of persistent pain is amongst the most challenging tasks in 
clinical practice today, directly affecting the lives of millions. Systemic administration of 
established painkillers over a prolonged period of time tends to have serious side 
effects and is therefore considered suboptimal. When the peripheral source of pain can 
be localized, the existing methods of local anesthesia rely either on a direct repetitive 
drug injection or on the permanent drug-administering devices. Both methods have 
serious limitations pertinent to the patient's discomfort, the costs involved, and a 
possible systemic escape of the drug.  
The present study was prompted by the recent breakthroughs in the nano-engineering 
LbL technology, which enables micro-encapsulation and subsequent controllable 
release for the medicine of choice. A wide variety of substances have successfully been 
used as a payload for encapsulation (De Cock et al., 2010). The capsule size could be 
adjusted between 0.3 µm and >10 µm (determined by their template), whilst the surface 
functionality is provided by the outer layers. Crucially, the capsule shell permeability can 
be made sensitive to environmental variations (pH, temperature, osmolarity) (Delcea et 
al., 2011) or a remote physical stimulus (light, magnetic field, ultrasound) (Antipina and 
Sukhorukov, 2011), which is achieved through the incorporation of sensitive elements 
into the multilayer capsule wall (Munoz Javier et al., 2008, Pavlov et al., 2011, Pavlov et 
al., 2013, Gao et al., 2016). The LbL microcapsules normally show no toxicity or 
appreciable inflammation effects (Pavlov et al., 2011) and in most cases they are 
fabricated using standard biodegradable components (e.g., hyaluronic acid, dextran 
derivatives and other polysaccharides, gelatine and other peptides) approved by the 
FDA and equivalent European regulatory authorities for use in humans (Zhang et al., 
2013). They therefore generally meet the requirements for a safe drug delivery platform 
suitable for use in humans.  
In parallel, there has been a growing interest in the Na+ channel blocker QX-314, which 
appears to be more potent and longer-lasting in its analgesic effects in mammals, 
compared to the more traditional painkillers (Lim et al., 2007, Roberson et al., 2011, 
Zhao et al., 2014). It is also routinely used in experimental neurophysiology research for 
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dampening neuronal excitability. Although QX-314 is a membrane-impermeable 
compound which blocks Na+ channels from the cytoplasm side, studies in situ have 
established that it enters nerve cells through the TRP receptors subtypes TRPV1 and 
TRPA1 (Binshtok et al., 2007, Leffler et al., 2011, Stueber et al., 2016) and possibly also 
through a TRP-independent mechanism (Brenneis et al., 2014, Hofmann et al., 2014).  
Our research strategy sought to combine these two recent lines of enquiry, aiming to 
test it in a case study in rats whether encapsulated QX-314 could improve peripheral 
pain treatment compared to more traditional approaches. This strategy achieved several 
objectives. Firstly, we nano-engineered encapsulated QX-314, injected the 
microcapsules into individual nerve cells (in culture) and documented gradual 
suppression of excitability in individual neurons under whole-cell electrophysiological 
control. Secondly, we evaluated and adjusted the microcapsule properties in the target 
tissue areas in situ to ensure relatively slow, long-term local release of the encapsulated 
cargo. Thirdly, and perhaps most importantly, we found that a single local injection of 
encapsulated QX-314 had a robust anti-nociceptive effect in an animal model of 
persistent inflammatory pain in vivo. The effect, which lasted for more than one week, 
was documented using the semi-automated measurements of the pain threshold and 
camera-traced quantification of the animal locomotion and explorative behavior. The 
results were gauged against the groups of inflamed animals which received a single 
injection of either empty microcapsules or non-encapsulated QX-314, and also the 
control groups of non-inflamed animals or those with an injection of empty 
microcapsules. Finally, we established that, consistent with the previous observations, 
the prevalent cellular mechanism enabling intracellular QX-314 action is likely to involve 
TRPV1 receptors and that the microcapsules undergo robust biodegradation from Week 
5 post-injection onwards.  
Clearly, although the LbL microcapsules are proving themselves as a highly flexible 
method of drug encapsulation and delivery, the injection method described here 
provides relatively limited control over their precise positioning, dosage, and spread in 
the target tissue. Remote control of microcapsule movement inside tissue could further 
improve to the coordinate precision of drug delivery. Another promising objective for the 
future development is to equip the surface of microcapsules with physicochemical 
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properties that would help to recognize target tissue or cells. In terms of practical 
application, further tests are needed to establish the stability and the storage 
requirements for the microencapsulated medicine, including the costs involved. 
Nonetheless, the present results suggest that LbL microcapsules represent a promising 
approach to provide long-lasting, efficient and controllable focal delivery of anti-
nociceptive drugs, with limited side effects on the systemic level.  
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Figure 1. Encapsulated QX-314 delivered intracellularly gradually suppresses 
neuronal excitability in vitro.  
(A) A snapshot showing the suspension of nano-engineered microcapsules (magnified 
on the right), with encapsulated Alexa Fluor 488; confocal imaging (λx = 488 nm). 
(B) Monitoring gradual release of encapsulated Alexa Fluor 488 from microcapsules; 
ordinate, time course of average capsule fluorescence normalized to the initial 
value; solid line, best-fit bi-exponential approximation (with 0.04 and 0.96 partial 
weights, respectively; decay constants as shown; n = 1.6108 microcapsules).  
(C) Snapshots displaying the patch pipette tip filled with microcapsules (TRITC 
fluorescence) prior to patching (left), when targeting a cultured neuron (middle), 
and in whole-cell configuration 25 min following intracellular delivery of 
microcapsules (right; DIC + fluorescence images of the same cell).   
(D) Traces, examples of current-clamp recordings of neuronal firing in control 
condition and after injection of encapsulated QX-314 (immediately after breaking-
in and 20 min later, as indicated). Graph, statistical summary: time course of the 
maximal neuronal firing rate in control cells (no microcapsules; n = 17), with empty 
microcapsules injected (n = 12), encapsulated QX-314 injected (n = 18), with non-
capsulated QX-314 injected at 0.5 mM (n = 6) and 5 mM (n = 4), as indicated.  
(E) Left, examples of neuronal firing in response to a slow-ramp current after infusion 
of encapsulated QX-314 (left, 0 min and 20 min post injection in the same cell; 
dotted boxes indicate first spikes selected for comparisons); right, example of 
single action potential evoked in hippocampal neurons, with the estimated 
parameters indicated (FWHM, full width at half maximum).  
(F) Time course of the relative spike amplitude (left) and the spike overshoot 
(amplitude above 0 mV; right) in control condition (no capsules, black dots) and 
after intracellular delivery of encapsulated QX-314 (red dots), as indicated; spike 
sampling as shown in panel E (left); control, n = 9 neurons; encapsulated QX-314, 
n = 9 neurons.  
All data are shown as mean ± SEM. ** p < 0.01, *** p < 0.001 (unpaired t-test).  
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Figure 2.  Encapsulated QX-314 gradually increases cell input resistance of 
neurons while reducing their firing rate in a dose-dependent manner. 
(A) Traces, examples of the membrane potential response (top) to current step pulses 
(bottom) in the same neuron (control condition, no microcapsules) at two time 
points, as indicated. Dashed lines, time window (stable response) where the input 
resistance was estimated. Graph, examples of the current-voltage relationship at 
three time points, as indicated, in control conditions.  
(B) Examples of the current-voltage relationship at three time points, as indicated, 
after the injection of empty microcapsules.   
(C) Traces, examples of the membrane potential response (top) to a current injection 
(bottom) at three time points after intracellular delivery of encapsulated QX-314, as 
indicated. Graph, examples of the current-voltage relationship at three time points, 
as indicated, for the same cell.   
(D) Time course of the cell input resistance in control (n = 14 neurons), post-infusion 
of empty microcapsules (n = 15) or encapsulated QX-314 (n = 14), as indicated.  
(E) Traces, representative recordings of neuronal firing after whole-cell dialysis with 
different concentrations of QX-314, at two time points, as indicated.  
(F) Time course of the maximum cell firing rate for different concentrations of free QX-
314, compared with encapsulated QX-314, added to the intracellular medium, as 
indicated.  
Data are mean ± SEM; * p < 0.05 (unpaired t-test).  
 
 
Figure 3.  Long-lasting release of encapsulated cargo inside glabrous skin in situ.   
(A)  Left image, acute skin tissue preparation from plantar surface of the rat hind paw 
(DIC image) depicting region of interest (ROI, dotted rectangle). Right images, ROI 
enlarged and shown in fluorescence channel (λx
2P = 800 nm), depicting injected 
microcapsules (top, encapsulated Alexa Fluor 488), and the subsequently 
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positioned micropipette tip filled with free Alexa Fluor 488 (bottom); dotted line: 
line-scan position.  
(B) Concentration kinetics of encapsulated Alexa Fluor 488 release from 
microcapsules in situ (mean ± SEM, n = 10); red line, best fit bi-exponential 
approximation (τ1, τ2 - decay constants, 0.04 and 0.96 partial weights partial 
weights, respectively).  
(C) Image, example of line-scan (position in A, right bottom image; λx
2P = 800 nm) 
depicting the escape of non-capsulated Alexa Fluor 488 injected from the 
micropipette. Graph, concentration kinetics of free Alexa Fluor 488 injected from 
the micropipette (0.75 s pressure pulse) in situ; red line, best fit bi-exponential 
approximation (τ1, τ2 - decay constants, 0.08 and 0.92 partial weights, 
respectively).   
(D) Image, experimental arrangement for photon-counting of spatial Alexa Fluor 488 
fluorescence escape: a single microcapsule shown in 99% glycerol (arrow, 
depiction of the radial profile calculation). Graph, radial profiles of Alexa Fluor 488 
generated photon counts in two experimental conditions, as indicated (shaded 
area: capsule radius).  
(E) Image, example of a microcapsule in the epidermal-dermal area at different time-
points (0-7 h, as indicated) following injection into acute skin tissue in situ (arrow, 
depiction of the radial profile calculation). Graph, radial profiles of Alexa Fluor 488 
generated photon counts in the epidermal-dermal area, at different time points 
after injection, as indicated (shaded area: capsule radius).  
 
Figure 4. The anti-nociceptive effect of encapsulated QX-314 in a persistent pain 
model in rodents. 
(A) Image panels, examples of rat hind paw following injection of CFA with no 
treatment (top row) and with encapsulated QX-314 (~3 mM; bottom row) at 
different time points, as indicated; ipsi, ipsilateral, inflammatory side; contra: 
contralateral, non-inflamed, side. Graph, time course of the thermal nociceptive 
threshold in control (contralateral, n = 5 rats) and CFA-inflamed animals injected 
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with empty microcapsules (n = 5) or encapsulated QX-314 (~3 mM, n = 6) or non-
capsulated QX-314 (100 mM, n = 5), as indicated.  
(B) Time course of the thermal nociceptive threshold (normalized to that at the 
treatment onset, which is 24 hours post-CFA), for different dosage of encapsulated 
QX-314, as indicated: 10 µM (n = 6 rats), 1 mM (n = 8), 3 mM (n = 6), and 7.5 mM 
(n = 7).  
(C) Fluorescent image (FITC fluorescence, transverse skin tissue section) displaying 
the epidermal-dermal area (the rat hind paw) with scattered microcapsules on Day 
1 after microcapsule injection. 
(D) Time course of inflammatory hypersensitivity in rats with persistent peripheral 
inflammation following treatment with different amounts of QX-314 per capsule, as 
indicated (animals received the same overall dose of QX-314, 1 mM): 4.5 pg (n = 6 
rats), 10 pg (n = 8), 0 pg (empty, n = 5).  
(E) Time course of inflammatory hypersensitivity with QX-314 in microcapsules of 
different sizes (animals received the same overall dose of encapsulated QX-314, 3 
mM): 2 µm diameter (n = 6 rats), 1 µm (n = 9), empty (varied size, n = 5).  
Data are shown as mean ± SEM. ** p < 0.01 (one-way ANOVA with Bonferroni 
post hoc test for encapsulated QX-314 compared with empty microcapsules). 
 
Figure 5. Encapsulated QX-314 abolishes locomotive deficit and anxiety in 
animals with persistent peripheral inflammation.  
(A) Examples of the open-field test trajectory records taken from one animal at 
different time-points following CFA injection and treatment with encapsulated QX-
314 (1 mM, 1 d post-CFA), as indicated; D, overall distance (meters) travelled over 
10.0 min.  
(B) The effect of encapsulated QX-314 on animal locomotion: time course of the 
average exploration distance travelled by CFA-inflamed animals injected with 
encapsulated QX-314 (1 mM) or empty microcapsules, and by healthy animals (no 
CFA) injected with empty microcapsules.  
(C) The dose-effect of encapsulated QX-314 on exploratory activity in CFA-inflamed 
animals: time course of the average distance (normalized by that 1 d post-CFA) 
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travelled by CFA-inflamed rats; treatment with empty capsules (n = 5 rats), 10 µM 
encapsulated QX-314 (n = 5), 1 mM encapsulated QX-314 (n = 5), 3 mM 
encapsulated QX-314 (n = 9), 10 mM encapsulated QX-314 (n = 6), as indicated. 
(D) The effect of encapsulated QX-314 on the average speed that animals could 
develop following treatment; notations as in B.  
(E) The effect of encapsulated QX-314 on the animal’s anxiety, estimated as the 
average fraction (%) of time spent in the arena corners (correlative anxiety 
indicator; left) versus the arena center (anti-correlative anxiety indicator; right). 
Treatment with empty capsules (n = 5 rats), 10 µM encapsulated QX-314 (n = 5), 1 
mM encapsulated QX-314 (n = 5).   
Data are shown as mean ± SEM. * p < 0.05, ** p < 0.01 (one-way ANOVA with 
Bonferroni post hoc test). 
 
Figure 6. Microcapsules co-localize with peripheral nerve fibers, engage TRPV1-
mediated analgesic effect of QX-314, and degrade with a time.  
(A) Examples of immunohistology of glabrous skin tissue (individual focal planes 
shown) for microcapsules carrying encapsulated QX-314 (3 mM; TRITC 
fluorescence, red) surrounding peripheral nerve fibers (neuron-specific PGP9.5 
staining, green). Transverse skin sections (30 µm thick).  
(B) Time course of the thermal pain threshold in animals injected with capsaicin (1.5 
µg µl-1, n = 6 rats) or with capsaicin together with 7.4 mM QX-314 (non-capsulated, 
n = 6). Data are mean ± SEM. * p < 0.05, ** p < 0.01 (one-way ANOVA with 
Bonferroni post hoc test). 
(C) The z-axis profile of the microcapsule fluorescence (TRITC, λx
2P = 820 nm; 3 mM 
encapsulated QX-314, integrated fluorescence) inside the skin tissue from the rat 
hind paw at different times post-injection in vivo, as indicated. Total scanned 
volume ~370 µm3; 3 µm z-steps. 
(D) Averaged diameter of microcapsules inside the skin tissue from the rat hind paw at 
different time points post-injection in vivo, as indicated. The reduced diameter 
reflects progressive degradation of the outer capsule shell. Total number of 
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analyzed capsules is indicated; ** p < 0.01, *** p < 0.001 (one-way ANOVA with 
Fisher test).  
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(B) Encapsulated release 
τ1: 50 min 
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Additional Figure 1. Persistent inflammatory pain remains refractory to single 
focal injection of lidocaine.  
(A) Time course of the thermal nociceptive threshold (Hargreaves test) for the 
CFA-inflamed animals. Empty microcapsules (no payload) produced no 
changes in the CFA-induced peripheral thermal hypersensitivity in rats after 
injection into inflamed tissue, as indicated. Number of animals tested: n = 27 
with CFA-induced peripheral inflammation, no capsules, and n = 6 CFA-
inflamed rats injected with empty microcapsules.  
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(B) Time course of the thermal nociceptive threshold in CFA-inflamed animals with 
no treatment or injected with 2%, as indicated; n = 15 rats for CFA group, n = 
5 CFA-inflamed rats treated with lidocaine. 
Data are shown as mean ± SEM.  
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Additional Figure 2. Testing the concomitant effects of microcapsules in vivo.  
In non-inflamed animals, empty microcapsules (no payload, A) or encapsulated QX-
314 (B) had no effect on the time course of the thermal threshold of the ipsilateral 
hind paw compared to naïve animals (no microcapsules injected). Number of animals 
tested: n = 5 rats for empty microcapsules, n = 6 animals for encapsulated QX-314. 
Data are mean ± SEM. 
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Additional Figure 3. Encapsulated QX-314 improves impaired locomotion in 
animals with persistent peripheral inflammation.  
(A) The dose-dependent effect of encapsulated QX-314 on the average 
acceleration that animals with inflamed hind paw display in an open-field test 
following treatment, as indicated. Number of animals tested: n = 5 rats for 
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empty microcapsules, n = 4 animals for 1 mM encapsulated QX-314; n = 5 
animals for 10 M encapsulated encapsulated QX-314.   
(B) Time course of the average acceleration that animals with the CFA-inflamed 
hind paw display in an open-field test following lidocaine treatment (a single 
injection of 2% lidocaine) or injection of empty microcapsules, as indicated. 
Number of animals tested: n = 6 treated with lidocaine, n = 5 injected with 
empty microcapsules.   
Data are shown as mean ± SEM. * p < 0.05 (one-way ANOVA with Bonferroni post 
hoc test). 
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